Cargando…

Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: Potential implications for their clinical use

Mesenchymal stromal/stem cells (MSCs) have shown significant therapeutic potential, and have therefore been extensively investigated in preclinical studies of regenerative medicine. However, while MSCs have been shown to be safe as a cellular treatment, they have usually been therapeutically ineffec...

Descripción completa

Detalles Bibliográficos
Autores principales: Miceli, Vitale, Zito, Giovanni, Bulati, Matteo, Gallo, Alessia, Busà, Rosalia, Iannolo, Gioacchin, Conaldi, Pier Giulio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277962/
https://www.ncbi.nlm.nih.gov/pubmed/37342218
http://dx.doi.org/10.4252/wjsc.v15.i5.400
_version_ 1785060394744676352
author Miceli, Vitale
Zito, Giovanni
Bulati, Matteo
Gallo, Alessia
Busà, Rosalia
Iannolo, Gioacchin
Conaldi, Pier Giulio
author_facet Miceli, Vitale
Zito, Giovanni
Bulati, Matteo
Gallo, Alessia
Busà, Rosalia
Iannolo, Gioacchin
Conaldi, Pier Giulio
author_sort Miceli, Vitale
collection PubMed
description Mesenchymal stromal/stem cells (MSCs) have shown significant therapeutic potential, and have therefore been extensively investigated in preclinical studies of regenerative medicine. However, while MSCs have been shown to be safe as a cellular treatment, they have usually been therapeutically ineffective in human diseases. In fact, in many clinical trials it has been shown that MSCs have moderate or poor efficacy. This inefficacy appears to be ascribable primarily to the heterogeneity of MSCs. Recently, specific priming strategies have been used to improve the therapeutic properties of MSCs. In this review, we explore the literature on the principal priming approaches used to enhance the preclinical inefficacy of MSCs. We found that different priming strategies have been used to direct the therapeutic effects of MSCs toward specific pathological processes. Particularly, while hypoxic priming can be used primarily for the treatment of acute diseases, inflammatory cytokines can be used mainly to prime MSCs in order to treat chronic immune-related disorders. The shift in approach from regeneration to inflammation implies, in MSCs, a shift in the production of functional factors that stimulate regenerative or anti-inflammatory pathways. The opportunity to fine-tune the therapeutic properties of MSCs through different priming strategies could conceivably pave the way for optimizing their therapeutic potential.
format Online
Article
Text
id pubmed-10277962
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-102779622023-06-20 Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: Potential implications for their clinical use Miceli, Vitale Zito, Giovanni Bulati, Matteo Gallo, Alessia Busà, Rosalia Iannolo, Gioacchin Conaldi, Pier Giulio World J Stem Cells Review Mesenchymal stromal/stem cells (MSCs) have shown significant therapeutic potential, and have therefore been extensively investigated in preclinical studies of regenerative medicine. However, while MSCs have been shown to be safe as a cellular treatment, they have usually been therapeutically ineffective in human diseases. In fact, in many clinical trials it has been shown that MSCs have moderate or poor efficacy. This inefficacy appears to be ascribable primarily to the heterogeneity of MSCs. Recently, specific priming strategies have been used to improve the therapeutic properties of MSCs. In this review, we explore the literature on the principal priming approaches used to enhance the preclinical inefficacy of MSCs. We found that different priming strategies have been used to direct the therapeutic effects of MSCs toward specific pathological processes. Particularly, while hypoxic priming can be used primarily for the treatment of acute diseases, inflammatory cytokines can be used mainly to prime MSCs in order to treat chronic immune-related disorders. The shift in approach from regeneration to inflammation implies, in MSCs, a shift in the production of functional factors that stimulate regenerative or anti-inflammatory pathways. The opportunity to fine-tune the therapeutic properties of MSCs through different priming strategies could conceivably pave the way for optimizing their therapeutic potential. Baishideng Publishing Group Inc 2023-05-26 2023-05-26 /pmc/articles/PMC10277962/ /pubmed/37342218 http://dx.doi.org/10.4252/wjsc.v15.i5.400 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Review
Miceli, Vitale
Zito, Giovanni
Bulati, Matteo
Gallo, Alessia
Busà, Rosalia
Iannolo, Gioacchin
Conaldi, Pier Giulio
Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: Potential implications for their clinical use
title Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: Potential implications for their clinical use
title_full Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: Potential implications for their clinical use
title_fullStr Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: Potential implications for their clinical use
title_full_unstemmed Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: Potential implications for their clinical use
title_short Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: Potential implications for their clinical use
title_sort different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: potential implications for their clinical use
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277962/
https://www.ncbi.nlm.nih.gov/pubmed/37342218
http://dx.doi.org/10.4252/wjsc.v15.i5.400
work_keys_str_mv AT micelivitale differentprimingstrategiesimprovedistincttherapeuticcapabilitiesofmesenchymalstromalstemcellspotentialimplicationsfortheirclinicaluse
AT zitogiovanni differentprimingstrategiesimprovedistincttherapeuticcapabilitiesofmesenchymalstromalstemcellspotentialimplicationsfortheirclinicaluse
AT bulatimatteo differentprimingstrategiesimprovedistincttherapeuticcapabilitiesofmesenchymalstromalstemcellspotentialimplicationsfortheirclinicaluse
AT galloalessia differentprimingstrategiesimprovedistincttherapeuticcapabilitiesofmesenchymalstromalstemcellspotentialimplicationsfortheirclinicaluse
AT busarosalia differentprimingstrategiesimprovedistincttherapeuticcapabilitiesofmesenchymalstromalstemcellspotentialimplicationsfortheirclinicaluse
AT iannologioacchin differentprimingstrategiesimprovedistincttherapeuticcapabilitiesofmesenchymalstromalstemcellspotentialimplicationsfortheirclinicaluse
AT conaldipiergiulio differentprimingstrategiesimprovedistincttherapeuticcapabilitiesofmesenchymalstromalstemcellspotentialimplicationsfortheirclinicaluse